NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Does Halozyme Still Offer Value After a 44.5% Surge and Strong DCF Upside?

If you are wondering whether Halozyme Therapeutics at around $68 is still a smart buy, or if most of the upside is already priced in, you are not alone. This article is going to tackle that value question head on. The stock is up 7.4% over the last week and 42.0% year to date, even after a slightly softer 30 day patch with a 3.1% pullback, adding up to a 44.5% gain over the past year. Recent gains have largely been driven by growing investor confidence in Halozyme Therapeutics drug delivery...
NasdaqGS:CTSH
NasdaqGS:CTSHIT

Cognizant’s Expanded Microsoft AI Alliance and New AI Labs Might Change The Case For Investing In Cognizant Technology Solutions (CTSH)

Cognizant recently announced a series of multi-year agreements, including an AI-focused partnership with Microsoft, new AI-driven BPaaS and IT modernization deals with Bupa Hong Kong, ERIKS, and BayWa, alongside the opening of an India AI Lab and Cognizant Moment Studio in Bengaluru to deepen applied AI research and innovation. Together, these moves highlight how Cognizant is integrating agentic AI and sector-specific platforms into core client workflows, aiming to reposition itself as an...
NYSE:VG
NYSE:VGOil and Gas

Venture Global (VG): Reassessing Valuation After a Sharp Short-Term Rebound and Steep Year-to-Date Decline

Venture Global (VG) has quietly turned into a roller coaster for investors, with the stock jumping 4% in a day but still sitting deeply red over the past 3 months and year to date. See our latest analysis for Venture Global. That sharp 1 day and 7 day share price return rebound comes after months of heavy selling, with the 90 day and year to date share price returns still pointing to fading momentum as investors reassess both growth prospects and risk. Given how quickly sentiment can swing in...
NasdaqGM:STAA
NasdaqGM:STAAMedical Equipment

Is STAAR Surgical A Bargain After Years of Share Price Declines?

Wondering if STAAR Surgical at around $24 a share is a hidden bargain or a value trap? You are not alone, and that is exactly what we are going to unpack. The stock has been choppy, up 2.7% over the last week but down 13.6% over the past month. Despite being barely positive year to date at 0.4%, it is still sitting on steep losses of around 50% over three years and 70% over five. Those big swings are set against a backdrop of ongoing excitement around implantable Collamer lenses and the...
NasdaqGS:LAES
NasdaqGS:LAESSemiconductor

Is SEALSQ (LAES) Quietly Repositioning as a Post‑Quantum Cybersecurity Platform Play?

SEALSQ’s recently announced partnership with Airmod delivered a production-ready, open-source-enabled middleware stack built on SEALSQ Secure DevKits to speed deployment of quantum-resistant IoT devices, alongside appointing industry veteran Rolf Gobet to lead its Geneva Quantum Center of Excellence within the Europe-focused Quantum Corridor initiative. Together, the Airmod collaboration and Gobet’s leadership role highlight SEALSQ’s push to offer end-to-end post-quantum cybersecurity...